Search results for "Years"

showing 10 items of 187 documents

Planktic foraminiferal changes in the western Mediterranean Anthropocene

2021

The increase in anthropogenic induced warming over the last two centuries is impacting marine environment. Planktic foraminifera are a globally distributed calcifying marine zooplankton responding sensitively to changes in sea surface temperatures and interacting with the food web structure. Here, we study two high resolution multicore records from two western Mediterranean Sea regions (Alboran and Balearic basins), areas highly affected by both natural climate change and anthropogenic warming. Cores cover the time interval from the Medieval Climate Anomaly to present. Reconstructed sea surface temperatures are in good agreement with other results, tracing temperature changes through the Co…

010504 meteorology & atmospheric sciencesLast 1500 yearsPopulationClimate change02 engineering and technologyOceanography01 natural sciencesWestern Mediterranean SeaForaminiferaMediterranean seaAtlantic multidecadal oscillation0202 electrical engineering electronic engineering information engineeringeducationAnthropogenic warming0105 earth and related environmental sciencesGlobal and Planetary Changeeducation.field_of_studybiology020206 networking & telecommunicationsLast 1500 yearGlobigerina bulloidesPlanktic foraminiferabiology.organism_classificationOceanographyNorth Atlantic oscillationUpwellingNatural variabilityMarine surface productionGeology
researchProduct

2018

0301 basic medicineBurden of diseaseCancer Researchbusiness.industryCancermedicine.disease03 medical and health sciences030104 developmental biology0302 clinical medicineYears of potential life lostOncologyCancer incidence030220 oncology & carcinogenesismedicinebusinessDemographyJAMA Oncology
researchProduct

Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 3…

2017

Importance: Cancer is the second leading cause of death worldwide. Current estimates on the burden of cancer are needed for cancer control planning.Objective: To estimate mortality, incidence, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs) for 32 cancers in 195 countries and territories from 1990 to 2015.Evidence Review: Cancer mortality was estimated using vital registration system data, cancer registry incidence data (transformed to mortality estimates using separately estimated mortality to incidence [MI] ratios), and verbal autopsy data. Cancer incidence was calculated by dividing mortality estimates through the modeled MI ratio…

0301 basic medicineGerontologyCancer ResearchPopulationArticle03 medical and health sciences0302 clinical medicineBreast cancerGlobal healthcancerMedicineDisability-adjusted life yeareducationDisease burdeneducation.field_of_studyestimate mortalityCancer preventioncancer preventionbusiness.industryMortality rate1. No povertymedicine.disease3. Good health030104 developmental biologyYears of potential life lostOncology030220 oncology & carcinogenesisbusinessearly diagnosisDemography
researchProduct

Estimating Global Burden of Disease due to congenital anomaly: an analysis of European data

2017

ObjectiveTo validate the estimates of Global Burden of Disease (GBD) due to congenital anomaly for Europe by comparing infant mortality data collected by EUROCAT registries with the WHO Mortality Database, and by assessing the significance of stillbirths and terminations of pregnancy for fetal anomaly (TOPFA) in the interpretation of infant mortality statistics.Design, setting and outcome measuresEUROCAT is a network of congenital anomaly registries collecting data on live births, fetal deaths from 20 weeks’ gestation and TOPFA. Data from 29 registries in 19 countries were analysed for 2005–2009, and infant mortality (deaths of live births at age <1 year) compared with the WHO Mortality …

0301 basic medicineMalePediatrics030105 genetics & heredityInfant DeathGlobal Burden of Disease0302 clinical medicineCongenital anomaly ; DALY ; Global Burden of Disease ; YLL ; mortality.PregnancyPrenatal DiagnosisYLLEpidemiologyInfant MortalityPrevalenceMedicineEPIDEMIOLOGY030212 general & internal medicineRegistries1506DOWN-SYNDROMEPOPULATIONeducation.field_of_studyDALYAnomaly (natural sciences)Pregnancy OutcomeObstetrics and GynecologyGestational ageGeneral MedicineStillbirthUPDATED SYSTEMATIC ANALYSISPREVALENCEEuropeFetal Mortality/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingFemaleOriginal ArticleCHILD-MORTALITYAdultCOUNTRIESmedicine.medical_specialtyPopulationGestational AgeCongenital Abnormalities03 medical and health sciencesSDG 3 - Good Health and Well-beingJournal ArticleHumansCongenital anomalyAbortion Induced/statistics & numerical data; Adult; Congenital Abnormalities/diagnosis; Congenital Abnormalities/epidemiology; Europe/epidemiology; Female; Fetal Death/prevention & control; Fetal Mortality; Gestational Age; Global Burden of Disease/methods; Global Burden of Disease/statistics & numerical data; Humans; Infant; Infant Death/prevention & control; Infant Mortality; Infant Newborn; Male; Pregnancy; Pregnancy Outcome/epidemiology; Prenatal Diagnosis/methods; Prenatal Diagnosis/statistics & numerical data; Prevalence; Registries/statistics & numerical data; Stillbirth/epidemiology; Congenital anomaly; DALY; Global Burden of Disease; YLL; mortalityeducationFetal DeathPregnancybusiness.industryInfant NewbornInfantAbortion InducedNATIONAL CAUSESmedicine.diseasemortalityTRENDSInfant mortalityChild mortalityYears of potential life lostPediatrics Perinatology and Child HealthbusinessPRIMARY PREVENTIONDemography
researchProduct

Changes in life expectancy for cancer patients over time since diagnosis

2019

Highlights • Research question: how cancer impacts on LE changes during patients’ entire life • LE increased in patients surviving the first years and decreasing thereafter. • Patients’ LE in the end approached but seldom reached the general population’s LE. • This method describes when cancer survivors’ excess risk of death became negligible. • Life expectancy indicator is easy to be understood and interpreted by patients.

0301 basic medicinePediatricsmedicine.medical_specialtycancer survivorLife expectancyCancer survivorsPopulationYLL years of life lost(ICD-O-3) international classification of diseases for oncology third revisionSocio-culturaleLife expectancy Population-based cancer registry Relative survival Cancer Cancer survivors ItalySettore MED/42 - Igiene Generale E ApplicataRelative survival03 medical and health sciences0302 clinical medicineHealth careMedicineeducationlcsh:Science (General)Population-based cancer registryThyroid cancerCancerRS relative survivaleducation.field_of_studylcsh:R5-920MultidisciplinaryRelative survivalbusiness.industryAbsolute risk reductionCancermedicine.diseaseLE life expectancyNHL non-Hodgkin lymphoma030104 developmental biologyYears of potential life lostItalyISTAT national institute of statistics030220 oncology & carcinogenesisLife expectancy(ICD-10) international classification of diseases tenth revisionOriginal Articlebusinesslcsh:Medicine (General)lcsh:Q1-390Journal of Advanced Research
researchProduct

Cost-effectiveness of buffered soluble alendronate 70 mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy

2021

Summary The use of buffered soluble alendronate 70 mg effervescent tablet, a convenient dosing regimen for bisphosphonate therapy, seems a cost-effective strategy compared with relevant alternative treatments for postmenopausal women with osteoporosis aged 60 years and over in Italy. Introduction To assess the cost-effectiveness of buffered soluble alendronate (ALN) 70 mg effervescent tablet compared with relevant alternative treatments for postmenopausal osteoporotic women in Italy. Methods A previously validated Markov microsimulation model was adjusted to the Italian healthcare setting to estimate the lifetime costs (expressed in €2019) per quality-adjusted life-years (QALY) of buffered …

0301 basic medicinemedicine.medical_specialtyeconomic evaluationCost effectivenessCost-Benefit AnalysisEndocrinology Diabetes and Metabolismmedicine.medical_treatmentOsteoporosisUrology030209 endocrinology & metabolismAlendronate . Buffered soluble alendronate . Cost-effectiveness . Economic evaluation . Effervescent tablets . Osteoporosis . TreatmentAlendronate; Buffered soluble alendronate; Cost-effectiveness; Economic evaluation; Effervescent tablets; Osteoporosis; Treatment; Aged; Alendronate; Cost-Benefit Analysis; Female; Humans; Italy; Middle Aged; Observational Studies as Topic; Postmenopause; Quality-Adjusted Life Years; Tablets; Bone Density Conservation Agents; Osteoporosis; Osteoporosis Postmenopausal03 medical and health sciences0302 clinical medicinemedicineHumansEffervescent tabletOsteoporosis PostmenopausalAgedBone mineralPostmenopausal womenBone Density Conservation AgentstreatmentAlendronatebusiness.industrybuffered soluble alendronateMiddle AgedBisphosphonatemedicine.diseaseosteoporosisPostmenopauseObservational Studies as TopicDenosumabZoledronic acidItalyeffervescent tabletsPostmenopausalFemaleOriginal ArticleCost-effectivenessQuality-Adjusted Life Years030101 anatomy & morphologybusinessTabletsmedicine.drugOsteoporosis International
researchProduct

Remittance behaviours of foreigners in Italy

2015

This article investigates the determinants of remittance behaviours among foreigners in Italy and intends to gain a better understanding of the temporal pattern of remittances. The analysis is based on data from the 2009 “Italian Statistics on Income and Living Conditions of Households with Foreigners”. The decisions on whether to remit and how much to remit are separately yet simultaneously estimated using a zero-inflated beta regression model. The findings reveal that remittances are driven by a mix of altruistic and self-interest motives that may persist for many years. Many covariates included in the model have a different effect on the propensity to remit and on the relative amount of …

05 social sciencesremittanceFlexibility (personality)Settore SECS-S/04 - Demografiaforeigners eu-silc survey years since migration0506 political scienceSpecificationimmune system diseases0502 economics and businessDevelopment economics050602 political science & public administrationEconomicsDemographic economicsRemittance050207 economicsBeta regressionDemographyInternational Migration
researchProduct

2016

The Global Burden of Disease, Injuries, and Risk Factor study 2013 (GBD 2013) is the first of a series of annual updates of the GBD. Risk factor quantification, particularly of modifiable risk factors, can help to identify emerging threats to population health and opportunities for prevention. The GBD 2013 provides a timely opportunity to update the comparative risk assessment with new data for exposure, relative risks, and evidence on the appropriate counterfactual risk distribution. Attributable deaths, years of life lost, years lived with disability, and disability-adjusted life-years (DALYs) have been estimated for 79 risks or clusters of risks using the GBD 2010 methods. Risk-outcome p…

2. Zero hungerCost effectivenessbusiness.industryGeneral MedicineEnvironmental exposure3. Good healthYears of potential life lostRelative riskEnvironmental healthGlobal healthMedicineStatistics & numerical dataRisk factorRisk assessmentbusinessThe Lancet
researchProduct

2016

Background Non-fatal outcomes of disease and injury increasingly detract from the ability of the world's population to live in full health, a trend largely attributable to an epidemiological transition in many countries from causes affecting children, to non-communicable diseases (NCDs) more common in adults. For the Global Burden of Diseases, Injuries, and Risk Factors Study 2015 (GBD 2015), we estimated the incidence, prevalence, and years lived with disability for diseases and injuries at the global, regional, and national scale over the period of 1990 to 2015. Methods We estimated incidence and prevalence by age, sex, cause, year, and geography with a wide range of updated and standardi…

2. Zero hungerGerontologyeducation.field_of_studySense organbusiness.industryPopulation1. No povertyGeneral MedicinePopulation health3. Good health03 medical and health sciencesEpidemiological transition0302 clinical medicineYears of potential life lostEnvironmental healthNeglected tropical diseasesLife expectancyGlobal healthMedicine030212 general & internal medicinebusinesseducation030217 neurology & neurosurgeryThe Lancet
researchProduct

2016

Summary Background Improving survival and extending the longevity of life for all populations requires timely, robust evidence on local mortality levels and trends. The Global Burden of Disease 2015 Study (GBD 2015) provides a comprehensive assessment of all-cause and cause-specific mortality for 249 causes in 195 countries and territories from 1980 to 2015. These results informed an in-depth investigation of observed and expected mortality patterns based on sociodemographic measures. Methods We estimated all-cause mortality by age, sex, geography, and year using an improved analytical approach originally developed for GBD 2013 and GBD 2010. Improvements included refinements to the estimati…

2. Zero hungerGerontologyeducation.field_of_studybusiness.industryMortality ratePopulation1. No povertyGeneral Medicine030204 cardiovascular system & hematologyVerbal autopsy3. Good health03 medical and health sciencesEpidemiological transition0302 clinical medicineYears of potential life lostLife expectancyCompensation law of mortalityMedicine030212 general & internal medicinebusinesseducationDemographyCause of deathThe Lancet
researchProduct